Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$59.95 - $92.06 $188,063 - $288,792
-3,137 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$132.81 - $182.18 $31.3 Million - $43 Million
-235,985 Reduced 98.69%
3,137 $438,000
Q4 2020

Feb 16, 2021

BUY
$138.17 - $184.34 $13 Million - $17.3 Million
93,969 Added 64.74%
239,122 $41.4 Million
Q3 2020

Nov 13, 2020

SELL
$114.09 - $145.51 $5.43 Million - $6.93 Million
-47,601 Reduced 24.7%
145,153 $20.2 Million
Q2 2020

Aug 13, 2020

BUY
$89.45 - $129.85 $17.2 Million - $25 Million
192,754 New
192,754 $23 Million
Q1 2020

May 15, 2020

SELL
$70.23 - $144.31 $16.7 Million - $34.3 Million
-237,883 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$76.41 - $117.54 $1.01 Million - $1.56 Million
-13,244 Reduced 5.27%
237,883 $28 Million
Q3 2019

Nov 14, 2019

BUY
$61.52 - $91.1 $5.52 Million - $8.18 Million
89,806 Added 55.67%
251,127 $21.6 Million
Q2 2019

Aug 14, 2019

BUY
$58.04 - $66.99 $9.36 Million - $10.8 Million
161,321 New
161,321 $10.5 Million

Others Institutions Holding NVRO

About NEVRO CORP


  • Ticker NVRO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,387,800
  • Market Cap $133M
  • Description
  • Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...
More about NVRO
Track This Portfolio

Track Tiger Eye Capital LLC Portfolio

Follow Tiger Eye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tiger Eye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tiger Eye Capital LLC with notifications on news.